Vycor Medical Inc Overview
Pro stress-test →Vycor Medical designs, develops, and markets neurological medical devices and therapies through two segments: Vycor Medical, which provides the ViewSite Brain Access System (VBAS), a retraction and access system for minimally invasive brain and spine surgeries, and NovaVision, which offers non-invasive computer-based rehabilitation therapies for patients with vision impairment from stroke or brain injury. The company reported 2025 revenue of $1.86M, up 17% year-over-year, driven primarily by international growth.
Strategic Profile
Pro stress-test →VBAS is a high-margin neurosurgery device experiencing strong revenue growth with 85% gross margins. 2025 marked a turnaround milestone with operating profit of $33,900 compared to an operating loss of $(9,145) in 2024. However, the company faces a critical liquidity challenge with a $4.15 million working capital deficiency and may lack sufficient cash through November 2026 without additional funding.
Competitive Landscape
Pro stress-test →VYCO operates as a micro-cap with $1.59M trailing twelve-month revenue in a niche between medtech giants (Medtronic, Stryker, Integer Holdings), positioning it as a potential acquisition target if capital structure challenges are resolved. The company competes in minimally invasive neurosurgery access systems, a consolidating market dominated by large diversified medical device manufacturers.
Industry Context
Vycor Medical Inc operates in Minimally invasive neurosurgery devices.
Key facts
Founded: 2005 · Headquarters: Boca Raton, Florida · Employees: N/A · Revenue: $1.86M (2025) · Market cap: N/A